Oxurion
Heverlee
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide, as well as other conditions, including wet age-related macular degeneration (AMD) and retinal vein occlusion (RVO).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $194.2M
- Funding stage: IPO
- Last round: Post-IPO Debt (Apr 2024)
- Ticker: ebr:OXUR
- Website: oxurion.com
- Phone: +32 16 75 13 10
Industries & Categories
Biotechnology, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/oxurion-169185 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.